scFv-based "Grababody" as a general strategy to improve recruitment of immune effector cells to antibody-targeted tumors.
about
Interference-Free HER2 ECD as a Serum Biomarker in Breast Cancer.Facile method for the site-specific, covalent attachment of full-length IgG onto nanoparticlesLysosome-dependent p300/FOXP3 degradation and limits Treg cell functions and enhances targeted therapy against cancers.Empowering scFv with effector cell functions for improved anticancer therapeutics.Tumor Associated Macrophages as Therapeutic Targets for Breast Cancer.A targeted immunotherapy approach for HER2/neu transformed tumors by coupling an engineered effector domain with interferon-γ.
P2860
scFv-based "Grababody" as a general strategy to improve recruitment of immune effector cells to antibody-targeted tumors.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
scFv-based "Grababody" as a ge ...... s to antibody-targeted tumors.
@ast
scFv-based "Grababody" as a ge ...... s to antibody-targeted tumors.
@en
type
label
scFv-based "Grababody" as a ge ...... s to antibody-targeted tumors.
@ast
scFv-based "Grababody" as a ge ...... s to antibody-targeted tumors.
@en
prefLabel
scFv-based "Grababody" as a ge ...... s to antibody-targeted tumors.
@ast
scFv-based "Grababody" as a ge ...... s to antibody-targeted tumors.
@en
P2093
P2860
P1433
P1476
scFv-based "Grababody" as a ge ...... s to antibody-targeted tumors.
@en
P2093
Hongtao Zhang
Yasuhiro Nagai
Zhiqiang Zhu
P2860
P304
P356
10.1158/0008-5472.CAN-12-3920
P407
P577
2013-02-08T00:00:00Z